Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Status:
Completed
Trial end date:
2009-02-01
Target enrollment:
Participant gender:
Summary
The use of smokeless tobacco (ST) as a substitute for cigarette smoking has been suggested
since it is considered by some to be a less harmful tobacco product (Russell, Jarvis and
Feyerabend, 1980; Russell et al, 1981; Rodu, 1994). ST does not have the volatile
constituents and carbon monoxide (CO) that are found in cigarette smoke. Since ST is not
smoked there would be less risk of cardiovascular and lung disease. In addition the harm
associated with second hand smoke would be eliminated. Although the health risks are reduced
in ST users, they still exist due to the presence of nitrosamines found in ST. A better
approach would be to use nicotine replacement that did not contain carcinogens, however the
cost of such NRT could be prohibitive especially in third world countries where the rate of
smoking is continuing to rise and the per capita income is much lower than in the United
States.
Purpose: The goal of this study is to evaluate the health effects of Camel Snus, the new oral
tobacco product produced by RJ Reynolds and Taboka, produced by Phillip Morris. These
products are pasteurized rather than fermented and contain less moisture to eliminate
spitting. They are marketed as an alternative to cigarette smoking.
Phase:
Phase 2
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute
Collaborators:
National Cancer Institute (NCI) National Institute on Drug Abuse (NIDA)